Novel Biomarkers of Hepatobiliary Tumors

Guest Editor:

Dr. Takahiro Kodama
Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita 565-0871, Japan

Deadline for manuscript submissions:
30 November 2024

Message from the Guest Editor

Dear Colleagues,

Hepatobiliary tumors including hepatocellular carcinoma (HCC), intracellular cholangiocarcinoma (ICC), and extrahepatic biliary tract cancer (BTC) are lethal malignancies. They are frequently diagnosed at inoperable advanced stages so detection markers with high sensitivity and specificity are highly desired. In addition, even after curative therapy such as locoregional treatment or surgery, tumors especially HCC frequently relapse. Therefore, it is also important to develop predictive biomarkers for tumor recurrence. Several molecular targeted drugs including angiogenesis and immune checkpoint inhibitors have been recently developed but their response rates were still unsatisfactory and there are no predictive biomarkers for their efficacy. Recent technological advances are capable of using a variety of biospecimens (e.g., tissue, blood, urine, and so on) and biomaterials (e.g., DNA, RNA, protein, miRNA) as potential biomarkers.

For this Special Issue of *Cancers*, we will welcome original research and review articles that focus on recent advances in the area of biomarker research targeting hepatobiliary cancer.

Dr. Takahiro Kodama
Guest Editor

mdpi.com/si/157208

Special Issue

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us